1. The above chart presented comparison between ATS (0072) with all glove counters for the last 30 days. ATS standout from the rest of the glove counters with a gain of 85.71% while the rest have actually fallen negative over the same period of time. ATS outstanding gain remained extra-originally higher than the rest despite falling off it's peak in mid Nov.

Source file link - https://drive.google.com/file/d/1PEt5D7S-4KrJd4JfgvopIui8oMdwYSP_/view?usp=sharing . Credit to Shariwu.

2. The most compherensive Price / PE projection that computed on it's monthly production capacity basis, average profit margin and PE projection from peer. At PE 20, ATS's price could reach between RM0.50 in Q121 and RM1.40 by Q221 when full production line running. From it's current price as on 30/11 at RM0.20, this will return a 150% by Q121 and 700% by Q221.

The projection is base on production capacity projection but in actual reality, market sentiment is always ahead of reality. Carepls PE peaked at 65X in Aug 20 before fallen to it's current level of 17X . IF ATS could replicate such performance, it's potential return could reach RM4.60, a whopping 2,200% ROI.

3. Successful Full Dip Run & CE Marking Approval.

https://youtu.be/o5aYBLshiX0

The line is tested full dip run successfully on  26 Dec 2020 and obtained CE Marking approval to export to Europe countries.

Everyone has a freedom of choice, one could choose to 

Option 1 - Early entry at low to maximise return

Option 2 - Wait till production commencement to chase high.

Option 3 - Stay aside and miss out extra-ordinary high ROI.

This is probably the last opportunity to ride on the glove wave in the once in a century pandemic.

$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
Telegram Group - ATIAN Club Enrolment - https://forms.gle/eL43VzhLq8qeESx36
To get the latest updates, facts and constructive discussion for ATS (0072)
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

Disclosure / Disclaimer :  

The author hold shares and interest in ATS and related stocks, thus readers are advised to perform their own due diligence and research before making any decision. This is NOT a recommendation to buy / hold / sell nor providing a financial advice / consultancy. Any information shared is purely for educational purposes only. Past performance is not indicative of future result and share trading is speculative in nature. All readers are strictly on Trade At Your Own Risk.